This brand name is authorized in Nigeria.
The drug ANATE contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
220236ED28 - AMODIAQUINE
|
2
|
UNII
60W3249T9M - ARTESUNATE
|
|
Artesunate is a semi-synthetic artemisinin derivative, indicated for the initial treatment of severe malaria in adults and children. The antimalarial mechanism of action of artesunate is generally thought to depend upon activation involving iron-mediated cleavage of the endoperoxide bridge of DHA to generate an unstable organic free radical followed by alkylation, where the free radical binds to malarial proteins leading to destruction of parasite membranes. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| 04-9256 | Tablet | Anate Tablets TAB 50 mg; 150 mg 1 x 6's (in blister) | Tablets | 26/08/2021 |
| 04-9257 | Granules | Anate Powder GRAN 25 mg; 75 mg 2 x 3's (in sachets) | Granules | 26/08/2021 |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | 04-9256, 04-9257 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.